MedTrace Logo

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

NCT05224492 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-02-07

No results posted yet for this study

Summary

Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.

Conditions

  • HIV Infections

Interventions

DRUG

Sulforaphane

40 mg of Sulforaphane powder once daily.

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Sunshine Specialty Health Care

    lead OTHER

Principal Investigators

  • Jose A. Giron, MD · Sunshine Specialty Health Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-21
Primary Completion
2022-07-21
Completion
2022-09-21
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224492 on ClinicalTrials.gov